These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25201862)

  • 1. Refractory subacute cutaneous lupus erythematous responding to a single course of belimumab: a new anti-BLyS human monoclonal antibody.
    Husein-ElAhmed H; Callejas-Rubio JL; Rios-Fernandez R; Ortego-Centeno N
    Indian J Dermatol Venereol Leprol; 2014; 80(5):477-8. PubMed ID: 25201862
    [No Abstract]   [Full Text] [Related]  

  • 2. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA; Thompson A; Tang Y; Hammer AE; Molta CT; Gordon D
    Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recommendations on the use of belimumab in systemic lupus erythematosus. GEAS-SEMI Clinical Practice Guide].
    Ramos-Casals M; Ruiz-Irastorza G; Jiménez-Alonso J; Khamashta MA;
    Rev Clin Esp (Barc); 2013; 213(1):42-58. PubMed ID: 23266125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP; D'Cruz DP
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Belimumab in systemic lupus erythematosus: a guide for its use in the daily practice].
    Ramos-Casals M; Ruiz-Irastorza G; Jiménez-Alonso J; Khamashta MA;
    Rev Clin Esp (Barc); 2013; 213(1):66-7. PubMed ID: 23565550
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-BLyS Treatment of 36 Israeli Systemic Lupus Erythematosus Patients.
    Sthoeger Z; Lorber M; Tal Y; Toubi E; Amital H; Kivity S; Langevitz P; Asher I; Elbirt D; Agmon Levin N
    Isr Med Assoc J; 2017 Jan; 19(1):44-48. PubMed ID: 28457114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity.
    Sjöwall C; Cöster L
    Scand J Rheumatol; 2014; 43(5):428-30. PubMed ID: 24689946
    [No Abstract]   [Full Text] [Related]  

  • 9. [Lupus erythematosus treatment with belimumab in daily practice: Retrospective study of 15 patients].
    Garval E; Pennaforte JL; Jaussaud R; Servettaz A; Bernard P; Reguiai Z
    Ann Dermatol Venereol; 2018 Jan; 145(1):5-12. PubMed ID: 29113694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
    J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
    Mosak J; Furie R
    Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belimumab in systemic lupus erythematosus -- what can be learned from longterm observational studies?
    Bengtsson AA
    J Rheumatol; 2014 Feb; 41(2):192-3. PubMed ID: 24488851
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.
    Wallace DJ; Navarra S; Petri MA; Gallacher A; Thomas M; Furie R; Levy RA; van Vollenhoven RF; Cooper S; Zhong ZJ; Freimuth W; Cervera R;
    Lupus; 2013 Feb; 22(2):144-54. PubMed ID: 23213069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Established organ damage reduces belimumab efficacy in systemic lupus erythematosus.
    Parodis I; Gomez A; Emamikia S; Chatzidionysiou K
    Ann Rheum Dis; 2019 Jul; 78(7):1006-1007. PubMed ID: 30610063
    [No Abstract]   [Full Text] [Related]  

  • 15. Post-marketing experiences with belimumab in the treatment of SLE patients.
    Askanase AD; Yazdany J; Molta CT
    Rheum Dis Clin North Am; 2014 Aug; 40(3):507-17, viii. PubMed ID: 25034159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belimumab for the treatment of recalcitrant cutaneous lupus.
    Vashisht P; Borghoff K; O'Dell JR; Hearth-Holmes M
    Lupus; 2017 Jul; 26(8):857-864. PubMed ID: 28121495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab.
    Sciascia S; Rubini E; Radin M; Cecchi I; Rossi D; Roccatello D
    Ann Rheum Dis; 2018 Nov; 77(11):1694-1695. PubMed ID: 29776976
    [No Abstract]   [Full Text] [Related]  

  • 18. Belimumab and the measurement of fatigue.
    Mazzoni D
    Ann Rheum Dis; 2015 Sep; 74(9):e53. PubMed ID: 25862616
    [No Abstract]   [Full Text] [Related]  

  • 19. Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?
    Runkel L; Stacey J
    Expert Opin Biol Ther; 2014 Apr; 14(4):491-501. PubMed ID: 24490627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus: a case report.
    Danve A; Perry L; Deodhar A
    Semin Arthritis Rheum; 2014 Oct; 44(2):195-7. PubMed ID: 25005336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.